BioSpace News Archive

RaySearch Laboratories AB (publ) announces that its advanced deep learning segmentation functionality for lung delineation in breast radiation therapy has been carried out using treatment planning system RayStation® * at Leeds Cancer Centre (LCC) in the UK.

Spacelabs Healthcare, a global designer and manufacturer of patient monitoring and diagnostic cardiology solutions, today announced that it has acquired an innovative cloud platform developed by BoxView, LLC (“Boxview”).

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will host a key opinion leader (KOL) discussion via webcast entitled “An Uncomfortable Discussion: The Immediate Need in Treating Women with Vaginal Yeast Infections” on Tuesday, July 14, 2020 at 10am Eastern Time.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection

Chemistree Technology Inc. (CSE: CHM) and (CSE: CHM.wt) (US OTCQB: CHMJF) (the “Company” or “Chemistree”) is pleased to announce that, further to the news releases dated June 15th and 18th, 2020, the first tranche of the investment into Immuoflex Therapeutics (“ImmunoFlex”) has now closed.

MammoScreen ™ , the explainable and actionable artificial intelligence (AI) based software assisting Radiologists in reading screening mammograms, received 510(k) clearance K192854 from the U.S. Food and Drug Admin

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, the Newfoundland and Labrador Prescription Drug Program (NLPDP) and the Yukon Drug Formulary for the treatment of Juvenile Idiopathic Arthritis (JIA). TH has also been approve

- Five coagulation researchers named this year’s recipients - Professor Heimburger Awards and ISTH Virtual Congress sponsorship showcase CSL Behring’s commitment to hematology research

R+D Custom Automation, a privately-owned U.S. provider of fully customized automation systems, has announced an agreement with SiO2 Materials Science.

Medela’s Healthcare business receives prestigious recognition for its ongoing efforts to support WOC Nurses across the country